Silence Therapeutics

Silence Therapeutics PLC

Company type	Public (Nasdaq: SLN)
Industry	Pharmaceuticals
Founded	1994
Headquarters	Hammersmith, London
Number of employees	120
Website	www.silence-therapeutics.com

Silence Therapeutics (Nasdaq: SLN^[1]) is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.^[2]

Development

Silence Therapeutics develops medicines related to RNA interference or RNAi to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet needs. Silence's mRNA GOLD platform can be used to create siRNAs (short interfering RNAs) that target and silence disease-associated genes in the liver.^{[citation needed]}

Silence Therapeutic's product candidates include SLN124 for hematological diseases^{[citation needed]} and zerlasiran (formerly SLN360) for reducing cardiovascular risk in people born with high levels of lipoprotein(a),^{[citation needed]} a genetic risk factor for cardiovascular disease. The company reported in November 2023 that a phase 1 study showed injection of repeated doses reduced patients' baseline of Lp(a) by up to 99 per cent for 90 days after.^[3]

Partnerships

Silence Therapeutics is under the stewardship of CEO Craig Tooman, and has established partnerships with pharmaceutical companies, such as AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others.^[4]

References

^ "Google Finance Stock Exchange listing for Silence Therapeutics".
^ "About us". silence-therapeutics.com. Archived from the original on 26 March 2023. Retrieved 26 June 2023.
^ "Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease". DAIC. 10 November 2023. Retrieved 23 August 2024.
^ "Transcript : Silence Therapeutics plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 09". MarketScreener. 12 January 2023. Retrieved 23 August 2024.

External links

Official website

Pharmaceutical and biotechnology industry in the United Kingdom

Companies

Current	AAH Pharmaceuticals Alliance Boots Astex AstraZeneca (MedImmune) BTG Cyclacel Dechra Pharmaceuticals GE HealthCare Genus GSK Hikma Pharmaceuticals Indivior IXICO MacFarlan Smith Mundipharma Norbrook Group Oxford Biomedica Pfizer UK Proximagen Silence Therapeutics TBS GB Vectura Vernalis ViiV Healthcare
Defunct	Allen & Hanburys Amersham Beecham Group Cambridge Antibody Technology Celltech Chiroscience The Distillers Company Fisons Glaxo Wellcome ICI Phytopharm Reliant Pharmaceuticals Renovo Shire Unipath Zeneca